Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain (LSRP)GlobeNewsWire • 06/27/22
5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And MoreBenzinga • 06/21/22
5 Short Squeeze Candidates To Watch This Week: TherapeuticsMD Tops List While This Arts And Crafts Retailer Joins The LeaderboardBenzinga • 06/13/22
5 Short Squeeze Candidates To Watch This Week: Vertex Energy Tops List, Medavail Holdings And Camping World Remain ElevatedBenzinga • 05/16/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eliem Therapeutics, Inc. - ELYMNewsfile Corp • 05/09/22
Eliem Therapeutics, Inc. (ELYM) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 05/09/22
Eliem Therapeutics shares sink more than 50% after lead program fails to show benefit in clinicGeekWire • 04/25/22
Eliem Therapeutics Appoints Susan Franks as Senior Vice President and Head of Regulatory AffairsGlobeNewsWire • 04/05/22
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial and Business HighlightsGlobeNewsWire • 03/07/22
Eliem Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewsWire • 02/11/22
Eliem Therapeutics Host Virtual Investor Event Featuring Opinion Leaders in Chronic Pain Research on February 16, 2022GlobeNewsWire • 02/07/22
Eliem Therapeutics Provides Program Updates and an Overview of Expected Near-Term MilestonesGlobeNewsWire • 01/18/22
Eliem Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 08/13/21
Eliem Therapeutics files for IPO as another Seattle-area biotech firm set to go publicGeekWire • 07/19/21